Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,080
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
Earnings Preview: REGN to Report Financial Results Pre-market on October 31
$Regeneron Pharmaceuticals(REGN.US)$ is scheduled to release its financial results pre-market on October 31 ET. Earnings PreviewAnalysts estimate $Regeneron Pharmaceuticals(REGN.US)$ to post revenue
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Regeneron Pharmaceuticals Analyst Ratings
Lilly's Ebglyss Shown to Be Effective in Former Dupixent Users